Who are MapLight Therapeutics, Inc.'s main suppliers?

MapLight Therapeutics, Inc. (MPLT) key suppliers include: MICHAEL-J-FOX-FOUNDATION. View the full supplier network at chainsifter.com/chain/MPLT.

Who are MapLight Therapeutics, Inc.'s major customers?

MapLight Therapeutics, Inc. (MPLT) key customers include: Bristol-Myers Squibb Company, Bristol-Myers Squibb Company, Bristol-Myers Squibb Co, Bristol-Myers Squibb Co, Johnson & Johnson and 13 more. View the full customer network at chainsifter.com/chain/MPLT.

What sector is MapLight Therapeutics, Inc. in?

MapLight Therapeutics, Inc. (MPLT) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

MapLight Therapeutics, Inc. (MPLT) Supply Chain: 21 Verified Relationships

1Suppliers

18Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

MapLight Therapeutics, Inc. (MPLT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

22Total relationships

2Distinct source URLs

4High confidence

0.726Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

MapLight Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
MICHAEL-J-FOX-FOUNDATION	MICHAEL-J-FOX-FOUNDATION	92%	Between February 2020 and August 2022, the Company executed four grant agreements (the "Grants") with the Michael J. Fox Foundation for the purpose of researching Parkinson's disease.

MapLight Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
BMY	Bristol-Myers Squibb Company	72%	. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges…
BMY	Bristol-Myers Squibb Company	72%	Reciprocal relationship from BMY graph: Reciprocal relationship from MPLT graph: . Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For …
BMYMP	Bristol-Myers Squibb Co	72%	Reciprocal relationship from BMYMP graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from BMYM…
BMYMP	Bristol-Myers Squibb Co	72%	. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from MPLT graph: . Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For …
JNJ	Johnson & Johnson	72%	. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges…
NBIX	Neurocrine Biosciences, Inc.	72%	. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges…
NBIX	Neurocrine Biosciences, Inc.	72%	Reciprocal relationship from NBIX graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from NBIX g…
NMRA	Neumora Therapeutics, Inc.	72%	Reciprocal relationship from NMRA graph: Reciprocal relationship from MPLT graph: . Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For…
NMRA	Neumora Therapeutics, Inc.	72%	. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges…
SNYNF	Sanofi	72%	incident, third parties may gather, collect or infer sensitive data about us from public sources, data brokers or other means that reveal competitively sensitive details about our organization and co…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from MPLT graph: incident, third parties may gather, collect or infer sensitive data about us from public sources, data brokers or ot…
ACAD	ACADIA Pharmaceuticals Inc.	62%	Reciprocal relationship from ACAD graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from ACAD graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from ACAD g…
ACADIA-PHARMACEUTICALS-INC	ACADIA-PHARMACEUTICALS-INC	62%	. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges…
ALVARADO-THERAPEUTICS-INC	ALVARADO-THERAPEUTICS-INC	62%	d legislation and implemented regulations that are designed to control pharmaceutical and biological product pricing, including price or reimbursement constraints, discounts, restrictions on certain …
NASDAQ-STOCK-MARKET-LLC	NASDAQ-STOCK-MARKET-LLC	62%	fail to become profitable or sustain profitability on a continuing basis, then we may be unable to raise additional capital, maintain our research and development efforts, expand our business or cont…
RELATED-PARTY-TRANSACTIONS-STELLAROMICS-INC	RELATED-PARTY-TRANSACTIONS-STELLAROMICS-INC	62%	upfront and development milestone payments of $ 150,000 to NeuroSolis. In June 2025, the Company issued 26,607 shares of the Company's common stock to NeuroSolis upon the initiation of a Phase 2 clin…
SYREMIS-THERAPEUTICS-LTD	SYREMIS-THERAPEUTICS-LTD	62%	. Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges…

MapLight Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
MPLT-DEBT-17123	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
MPLT-DEBT	Debt stack $5.6M	90%	Market cache reports total debt of $5.6M.

MapLight Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for MapLight Therapeutics, Inc..

MapLight Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
MPLT-OWNER-GOLDMAN-SACHS-GROUP-INC	GOLDMAN SACHS GROUP INC	90%	13F overlay lists GOLDMAN SACHS GROUP INC as top holder; 81 tracked holders.

MapLight Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
BNRG	Brenmiller Energy Ltd	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
EMMA	Emmaus Life Sciences, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
BEAM	Beam Therapeutics Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2

MapLight Therapeutics, Inc. Supply Chain